US dermatology top boss moves to Danish biotech firm
Draupnir Bio, which landed DKK 225m from four venture funds last year, will soon get a new boss in the form of Andrew Hotchkiss, who has previously worked as the CEO of Dermira. Further, the company is upgrading its board with a former Abbvie and Amgen executive.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Danish biotech company, which raised DKK 225m (USD 36.2m) in capital in 2019 from a series of European venture funds including Novo Seeds will be changing its CEO.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Google app will help detect skin ailments
For subscribers
Almirall starts the year with solid growth
For subscribers
